Investment Thesis
Nkarta is a pre-revenue biotech company with zero commercialized products, burning $28.2M quarterly in operations against only $27.4M cash reserves. At current burn rates, the company faces immediate capital runway risk and is entirely dependent on successful clinical development and equity financing to survive.
Strengths
- Strong balance sheet with $285.9M stockholders' equity exceeding total assets of $372.1M
- Excellent liquidity position with 12.96x current ratio, indicating no near-term solvency risk if capital needs are met
- Zero debt burden eliminates interest obligations and financial covenant risk
Risks
- Zero revenue with no commercialized products; company remains in clinical/development stage
- Critical cash runway: $27.4M cash remaining with -$28.2M quarterly operating cash burn equates to ~3 months of operations
- Severe operating losses of -$30.9M and net losses of -$27.8M indicate R&D-intensive model with no offsetting revenue
- Complete dependence on successful clinical outcomes and capital markets for equity financing
- Negative free cash flow of -$28.6M indicates value destruction and inability to self-fund operations
Key Metrics to Watch
- Quarterly cash burn rate and cash position relative to operating runway
- Clinical trial milestones and regulatory pathway progression
- Capital raises and financing events to extend operational runway
Financial Metrics
Revenue
0.0
Net Income
-27.8M
EPS (Diluted)
$-0.37
Free Cash Flow
-28.6M
Total Assets
372.1M
Cash
27.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-9.7%
ROA
-7.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
12.96x
Quick Ratio
12.96x
Debt/Equity
0.00x
Debt/Assets
23.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:53:03.654594 |
Data as of: 2026-03-31 |
Powered by Claude AI